Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 11/2016

01-11-2016 | Review Article

Adipokine Pattern After Bariatric Surgery: Beyond the Weight Loss

Authors: Gian Franco Adami, Nicola Scopinaro, Renzo Cordera

Published in: Obesity Surgery | Issue 11/2016

Login to get access

Abstract

Besides the role in energy storing and body health isolating, adipose tissue produces proteins, the so-called adipokines, with pro-inflammatory or anti-inflammatory actions that contribute to metabolic control and to appetite and energy expenditure regulation. The marked adipose tissue loss following bariatric surgery corresponds to a rearrangement of serum adipokine pattern, with increase of anti-inflammatory and decrease of pro-inflammatory agents. This might play a relevant role in the postoperative improvement of metabolic conditions. However, after surgically induced weight loss, other investigations failed to evidence significant modifications of serum concentration of some adipokines. This review speculates that the composition of adipose tissue lost could influence postoperative changes in some adipokine concentration and that an adequate adipokine pattern plays a pivotal role for the long-term metabolic outcome.
Literature
1.
Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875–80.PubMedCrossRef
2.
LeRoith D, Novosyadlyy R, Gallagher EJ, Lann D, Vijayakumar A, Yakar S. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp Clin Endocrinol Diabetes. 2008;116(Suppl 1):S4–6. doi:10.​1055/​s-2008-1081488.PubMedCrossRef
3.
4.
Sjöström LV. Mortality of severely obese subjects. Am J Clin Nutr. 1992;55(2 Suppl):516S–23S.PubMed
5.
6.
Mason J, Willett WC, Stampfer MJ, et al. Body weight and mortality in women. N Engl J Med. 1995;333:677–85.CrossRef
7.
Seidell JC, Verschuren WM, van Leer EM, et al. Overweight, underweight, and mortality. A prospective study of 48,287 men and women. Arch Intern Med. 1996;156:958–63.PubMedCrossRef
8.
9.
10.
Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, Bucher HC, Nordmann AJ. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347:f5934. doi:10.​1136/​bmj.​f5934.PubMedPubMedCentralCrossRef
11.
12.
Scopinaro N, Marinari GM, Camerini GB, Papadia FS, Adami GF. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care. 2005;28(10):2406–11.PubMedCrossRef
13.
14.
Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid GM, Mattar S, Ramanathan R, Barinas-Mitchel E, Rao RH, Kuller L, Kelley D. Effect of laparoscopic roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238(4):467–84.PubMedPubMedCentral
15.
Adami G, Murelli F, Carlini F, Papadia F, Scopinaro N. Long-term effect of biliopancreatic diversion on blood pressure in hypertensive obese patients. Am J Hypertens. 2005;18(6):780–4.PubMedCrossRef
16.
Dhabuwala A, Cannan RJ, Stubbs RS. Improvement in co-morbidities following weight loss from gastric bypass surgery. Obes Surg. 2000;10(5):428–35.PubMedCrossRef
17.
Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753–61.PubMedCrossRef
18.
Sjöström L, Narbro K, Sjöström CD, et al. Swedish obese subjects study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.PubMedCrossRef
19.
Forbes GB. Human body composition, growth, aging, nutrition, and activity. Influence of nutrition. New York: Springer; 1987. p. 209–47.
20.
Scopinaro N. Biliopancreatic diversion. In: Lucchese M, Scopinaro N, editors. Minimally invasive bariatric and metabolic surgery, principles and technical aspects. New York: Springer; 2015. p. 209–26.CrossRef
21.
22.
Falkén Y, Hellström PM, Holst JJ, Näslund E. Changes in glucose homeostasis after roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab. 2011;96(7):2227–35. doi:10.​1210/​jc.​2010-2876.PubMedCrossRef
23.
Jacobsen SH, Olesen SC, Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, Worm D, Almdal T, Naver LS, Hvolris LE, Rehfeld JF, Wulff BS, Clausen TR, Hansen DL, Holst JJ, Madsbad S. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg. 2012;22(7):1084–96. doi:10.​1007/​s11695-012-0621-4.PubMedCrossRef
24.
25.
Mingrone G, Nolfe G, Gissey GC, Iaconelli A, Leccesi L, Guidone C, Nanni G, Holst JJ. Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion. Diabetologia. 2009;52(5):873–81. doi:10.​1007/​s00125-009-1288-9.PubMedCrossRef
26.
Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG. Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP-1, GLP-2 and PYY levels. Obes Surg. 2007;17(9):1193–8.PubMedCrossRef
27.
Major P, Matłok M, Pędziwiatr M, Migaczewski M, Zub-Pokrowiecka A, Radkowiak D, Winiarski M, Zychowicz A, Fedak D, Budzyński A. Changes in levels of selected incretins and appetite-controlling hormones following surgical treatment for morbid obesity. Wideochir Inne Tech Maloinwazyjne. 2015;10(3):458–65. doi:10.​5114/​wiitm.​2015.​54003.PubMedPubMedCentral
28.
29.
30.
31.
32.
Adami GF, Parodi RC, Papadia F, Marinari G, Camerini G, Corvisieri R, Scopinaro N. Magnetic resonance spectroscopy facilitates assessment of intramyocellular lipid changes: a preliminary short-term study following biliopancreatic diversion. Obes Surg. 2005;15(9):1233–7.PubMedCrossRef
33.
Samat A, Malin SK, Huang H, Schauer PR, Kirwan JP, Kashyap SR. Ghrelin suppression is associated with weight loss and insulin action following gastric bypass surgery at 12 months in obese adults with type 2 diabetes. Diabetes Obes Metab. 2013;15(10):963–6. doi:10.​1111/​dom.​12118.PubMedCrossRef
34.
Mans E, Serra-Prat M, Palomera E, Suñol X, Clavé P. Sleeve gastrectomy effects on hunger, satiation, and gastrointestinal hormone and motility responses after a liquid meal test. Am J Clin Nutr. 2015;102(3):540–7. doi:10.​3945/​ajcn.​114.​104307.PubMedCrossRef
35.
36.
Scopinaro N, Adami GF, Marinari GM, Gianetta E, Traverso E, Friedman D, Camerini G, Baschieri G, Simonelli A. Biliopancreatic diversion. World J Surg. 1998;22(9):936–46.PubMedCrossRef
37.
38.
39.
40.
Biter LU, Gadiot RP, Grotenhuis BA, Dunkelgrün M, van Mil SR, Zengerink HJ, Smulders JF, Mannaerts GH. The sleeve bypass trial: a multicentre randomized controlled trial comparing the long term outcome of laparoscopic sleeve gastrectomy and gastric bypass for morbid obesity in terms of excess BMI loss percentage and quality of life. BMC Obes. 2015;2:30. doi:10.​1186/​s40608-015-0058-0 .eCollection 2015PubMedPubMedCentralCrossRef
41.
42.
43.
Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008;34(1):2–11.PubMedCrossRef
44.
Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92(3):347–55.PubMedCrossRef
45.
46.
47.
48.
Bluher M. Importance of adipokines in glucose homeostasis. Diabetes Manage. 2013;3:389–40.CrossRef
49.
50.
51.
52.
53.
Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627–35.PubMedPubMedCentralCrossRef
54.
55.
Tseng YH, Kokkotou E, Schulz TJ, Huang TL, Winnay JN, Taniguchi CM, Tran TT, Suzuki R, Espinoza DO, Yamamoto Y, Ahrens MJ, Dudley AT, Norris AW, Kulkarni RN, Kahn CR. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature. 2008;454(7207):1000–4. doi:10.​1038/​nature07221.PubMedPubMedCentralCrossRef
56.
57.
Gustafson B, Hammarstedt A, Hedjazifar S, Hoffmann JM, Svensson PA, Grimsby J, Rondinone C, Smith U. BMP4 and BMP antagonists regulate human white and beige adipogenesis. Diabetes. 2015;64(5):1670–81. doi:10.​2337/​db14-1127.PubMedCrossRef
58.
Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, Shikata K, Hourai S, Futami J, Watanabe E, Matsuki Y, Hiramatsu R, Akagi S, Makino H, Kanwar YS. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A. 2005;102(30):10610–5.PubMedPubMedCentralCrossRef
59.
Youn BS, Klöting N, Kratzsch J, Lee N, Park JW, Song ES, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M, Blüher M. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008;57(2):372–7.PubMedCrossRef
60.
61.
Boucher J, Masri B, Daviaud D, Gesta S, Guigné C, Mazzucotelli A, Castan-Laurell I, Tack I, Knibiehler B, Carpéné C, Audigier Y, Saulnier-Blache JS, Valet P. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005;146(4):1764–71.PubMedCrossRef
62.
Tokunaga A, Miura A, Okauchi Y, Segawa K, Fukuhara A, Okita K, Takahashi M, Funahashi T, Miyagawa J, Shimomura I, Yamagata K. The-1535 promoter variant of the visfatin gene is associated with serum triglyceride and HDL-cholesterol levels in Japanese subjects. Endocr J. 2008;55(1):205–12.PubMedCrossRef
63.
Goktas Z, Moustaid-Moussa N, Shen CL, Boylan M, Mo H, Wang S. Effects of bariatric surgery on adipokine-induced inflammation and insulin resistance. Front Endocrinol [Lausanne]. 2013;4:69. doi:10.​3389/​fendo.​2013.​00069 .eCollection 2013
64.
Wolfe BE, Jimerson DC, Orlova C, Mantzoros CS. Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers. Clin Endocrinol. 2004;61(3):332–8.CrossRef
65.
Sentinelli F, Romeo S, Arca M, Filippi E, Leonetti F, Banchieri M, Di Mario U, Baroni MG. Human resistin gene, obesity, and type 2 diabetes: mutation analysis and population study. Diabetes. 2002;51(3):860–2.PubMedCrossRef
66.
Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab. 2002;13(1):18–23.PubMedCrossRef
67.
68.
Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006;354(24):2552–63.PubMedCrossRef
69.
Gómez-Ambrosi J, Rodríguez A, Catalán V, Ramírez B, Silva C, Rotellar F, Gil MJ, Salvador J, Frühbeck G. Serum retinol-binding protein 4 is not increased in obesity or obesity-associated type 2 diabetes mellitus, but is reduced after relevant reductions in body fat following gastric bypass. Clin Endocrinol. 2008;69(2):208–15.CrossRef
70.
Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, Eckardt K, Kaufman JM, Ryden M, Müller S, Hanisch FG, Ruige J, Arner P, Sell H, Eckel J. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60(7):1917–25. doi:10.​2337/​db10-1707.PubMedPubMedCentralCrossRef
71.
72.
Sell H, Blüher M, Klöting N, Schlich R, Willems M, Ruppe F, Knoefel WT, Dietrich A, Fielding BA, Arner P, Frayn KN, Eckel J. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care. 2013;36(12):4083–90. doi:10.​2337/​dc13-0496.PubMedPubMedCentralCrossRef
73.
74.
75.
76.
Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356(15):1517–26.PubMedCrossRef
77.
Dalmas E, Venteclef N, Caer C, Poitou C, Cremer I, Aron-Wisnewsky J, Lacroix-Desmazes S, Bayry J, Kaveri SV, Clément K, André S, Guerre-Millo MT. Cell-derived IL-22 amplifies IL-1β-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. Diabetes. 2014;63(6):1966–77. doi:10.​2337/​db13-1511.PubMedCrossRef
78.
79.
Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance [EGIR]. J Clin Invest. 1997;100(5):1166–73.PubMedPubMedCentralCrossRef
80.
Rull A, Camps J, Alonso-Villaverde C, Joven J. Insulin resistance, inflammation, and obesity: role of monocyte chemoattractant protein-1 [or CCL2] in the regulation of metabolism. Mediat Inflamm. 2010;2010. doi:10.​1155/​2010/​326580.
81.
Malavazos AE, Cereda E, Morricone L, Coman C, Corsi MM, Ambrosi B. Monocyte chemoattractant protein 1: a possible link between visceral adipose tissue-associated inflammation and subclinical echocardiographic abnormalities in uncomplicated obesity. Eur J Endocrinol. 2005;153(6):871–7.PubMedCrossRef
82.
83.
84.
Trayhurn P. Adipose tissue in obesity—an inflammatory issue. Endocrinology. 2005;146(3):1003–5.PubMedCrossRef
85.
86.
87.
88.
89.
Adami GF, Gradasch R, Andrageheri G, et al. Serum leptin and adiponectin concentration in type 2 diabetic patients in the short and in the long term following biliopancreatic diversion. Obes Surg. 2016. doi:10.​1007/​s11695-016-2126-z.
90.
Adami GF, Cordera R, Campostano A, Bressani A, Cella F, Scopinaro N. Serum leptin and weight loss in severely obese patients undergoing biliopancreatic diversion. Int J Obes Relat Metab Disord. 1998;22(8):822–4.PubMedCrossRef
91.
Leyvraz C, Verdumo C, Suter M, Paroz A, Calmes JM, Marques-Vidal PM, Giusti V. Changes in gene expression profile in human subcutaneous adipose tissue during significant weight loss. Obes Facts. 2012;5(3):440–51. doi:10.​1159/​000341137.PubMedCrossRef
92.
Vendrell J, Broch M, Vilarrasa N, Molina A, Gómez JM, Gutiérrez C, Simón I, Soler J, Richart C. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res. 2004;12(6):962–71.PubMedCrossRef
93.
94.
Marinari GM, Camerini G, Cella F, Scopinaro N, Adami GF. Short-term changes in serum leptin concentration following biliopancreatic diversion. Obes Surg. 2000;10(5):442–4.PubMedCrossRef
95.
Salani B, Briatore L, Andraghetti G, Adami GF, Maggi D, Cordera R. High-molecular weight adiponectin isoforms increase after biliopancreatic diversion in obese subjects. Obesity [silver. Spring. 2006;14(9):1511–4.
96.
Butner KL, Nickols-Richardson SM, Clark SF, Ramp WK, Herbert WGA. Review of weight loss following roux-en-Y gastric bypass vs restrictive bariatric surgery: impact on adiponectin and insulin. Obes Surg. 2010;20(5):559–68. doi:10.​1007/​s11695-010-0089-z.PubMedCrossRef
97.
98.
99.
Illán-Gómez F, Gonzálvez-Ortega M, Orea-Soler I, Alcaraz-Tafalla MS, Aragón-Alonso A, Pascual-Díaz M, Pérez-Paredes M, Lozano-Almela ML. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg. 2012;22(6):950–5. doi:10.​1007/​s11695-012-0643-y.PubMedCrossRef
100.
Côté M, Cartier A, Reuwer AQ, Arsenault BJ, Lemieux I, Després JP, Wareham NJ, Kastelein JJ, Boekholdt SM, Khaw KT. Adiponectin and risk of coronary heart disease in apparently healthy men and women [from the EPIC-Norfolk prospective population study]. Am J Cardiol. 2011;108(3):367–73. doi:10.​1016/​j.​amjcard.​2011.​03.​053.PubMedCrossRef
101.
Scopinaro N, Camerini G, Papadia F, Andraghetti G, Cordera R, Adami GF. Long-term clinical and functional impact of biliopancreatic diversion on type 2 diabetes in morbidly and non-morbidly obese patients. Surg Obes Relat Dis. 2016;12(4):822–7. doi:10.​1016/​j.​soard.​2015.​12.​011.PubMedCrossRef
102.
Hirsch FF, Pareja JC, Geloneze SR, Chaim E, Cazzo E, Geloneze B. Comparison of metabolic effects of surgical-induced massive weight loss in patients with long-term remission versus non-remission of type 2 diabetes. Obes Surg. 2012;22(6):910–7. doi:10.​1007/​s11695-012-0589-0.PubMedCrossRef
103.
Chen J, Pamuklar Z, Spagnoli A, Torquati A. Serum leptin levels are inversely correlated with omental gene expression of adiponectin and markedly decreased after gastric bypass surgery. Surg Endosc. 2012;26(5):1476–80. doi:10.​1007/​s00464-011-2059-5.PubMedCrossRef
104.
105.
Sams VG, Blackledge C, Wijayatunga N et al. Effect of bariatric surgery on systemic and adipose tissue inflammation. Surg Endosc. 2016;30(8):3499–504. doi:10.​1007/​s00464-015-4638-3.
106.
Netto BD, Bettini SC, Clemente AP, Ferreira JP, Boritza K, Souza Sde F, Von der Heyde ME, Earthman CP, Dâmaso AR. Roux-en-Y gastric bypass decreases pro-inflammatory and thrombotic biomarkers in individuals with extreme obesity. Obes Surg. 2015;25(6):1010–8. doi:10.​1007/​s11695-014-1484-7.PubMedCrossRef
107.
Botella-Carretero JI, Luque-Ramírez M, Alvarez-Blasco F, Peromingo R, San Millán JL, Escobar-Morreale HF. The increase in serum visfatin after bariatric surgery in morbidly obese women is modulated by weight loss, waist circumference, and presence or absence of diabetes before surgery. Obes Surg. 2008;18(8):1000–6. doi:10.​1007/​s11695-007-9369-7.PubMedCrossRef
108.
García-Fuentes E, García-Almeida JM, García-Arnés J, García-Serrano S, Rivas-Marín J, Gallego-Perales JL, Rojo-Martínez G, Garrido-Sánchez L, Bermudez-Silva FJ, Rodríguez de Fonseca F, Soriguer F. Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass. Obesity (Silver Spring). 2007;15(10):2391–5.CrossRef
109.
Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307(5708):426–30.PubMedCrossRef
110.
111.
Marantos G, Daskalakis M, Karkavitsas N, Matalliotakis I, Papadakis JA, Melissas J. Changes in metabolic profile and adipoinsular axis in morbidly obese premenopausal females treated with restrictive bariatric surgery. World J Surg. 2011;35(9):2022–30. doi:10.​1007/​s00268-011-1165-9.PubMedCrossRef
112.
Jankiewicz-Wika J, Kołomecki K, Cywiński J, Piestrzeniewicz K, Swiętosławski J, Stępień H, Komorowski J. Impact of vertical banded gastroplasty on body weight, insulin resistance, adipocytokine, inflammation and metabolic syndrome markers in morbidly obese patients. Endokrynol Pol. 2011;62(2):109–19.PubMed
113.
114.
Iqbal N, Seshadri P, Stern L, Loh J, Kundu S, Jafar T, Samaha FF. Serum resistin is not associated with obesity or insulin resistance in humans. Eur Rev Med Pharmacol Sci. 2005;9(3):161–5.PubMed
115.
Soriguer F, Garrido-Sanchez L, Garcia-Serrano S, Garcia-Almeida JM, Garcia-Arnes J, Tinahones FJ, Garcia-Fuentes E. Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus. Obes Surg. 2009;19(11):1574–80. doi:10.​1007/​s11695-009-9955-y.PubMedCrossRef
116.
Krist J, Wieder K, Klöting N, Oberbach A, Kralisch S, Wiesner T, Schön MR, Gärtner D, Dietrich A, Shang E, Lohmann T, Dreßler M, Fasshauer M, Stumvoll M, Blüher M. Effects of weight loss and exercise on apelin serum concentrations and adipose tissue expression in human obesity. Obes Facts. 2013;6(1):57–69. doi:10.​1159/​000348667.PubMedCrossRef
117.
Chang HM, Lee HJ, Park HS, Kang JH, Kim KS, Song YS, Jang YJ. Effects of weight reduction on serum vaspin concentrations in obese subjects: modification by insulin resistance. Obesity (Silver Spring). 2010;18(11):2105–10. doi:10.​1038/​oby.​2010.​60.CrossRef
118.
Handisurya A, Riedl M, Vila G, Maier C, Clodi M, Prikoszovich T, Ludvik B, Prager G, Luger A, Kautzky-Willer A. Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. Obes Surg. 2010;20(2):198–203. doi:10.​1007/​s11695-009-9882-y.PubMedCrossRef
119.
Klöting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schön MR, Stumvoll M, Blüher M. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun. 2006;339(1):430–6.PubMedCrossRef
120.
Tschoner A, Sturm W, Engl J, Kaser S, Laimer M, Laimer E, Weiss H, Patsch JR, Ebenbichler CF. Retinol-binding protein 4, visceral fat, and the metabolic syndrome: effects of weight loss. Obesity (Silver Spring). 2008;16(11):2439–44. doi:10.​1038/​oby.​2008.​391.CrossRef
121.
Haider DG, Schindler K, Prager G, Bohdjalian A, Luger A, Wolzt M, Ludvik B. Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab. 2007;92(3):1168–71.PubMedCrossRef
122.
123.
124.
Gaborit B, Jacquier A, Kober F, Abdesselam I, Cuisset T, Boullu-Ciocca S, Emungania O, Alessi MC, Clément K, Bernard M, Dutour A. Effects of bariatric surgery on cardiac ectopic fat: lesser decrease in epicardial fat compared to visceral fat loss and no change in myocardial triglyceride content. J Am Coll Cardiol. 2012;60(15):1381–9. doi:10.​1016/​j.​jacc.​2012.​06.​016.PubMedCrossRef
125.
126.
127.
Ritzel RA, Butler AE, Rizza RA, Veldhuis JD, Butler PC. Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care. 2006;29:717–8.PubMedCrossRef
128.
Saisho Y, Butler AE, Manesso E, Elashoff D, Rizza RA, Butler PC. β-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care. 2013;36:111–7.PubMedCrossRef
129.
Grams J, Garvey WT. Weight loss and the prevention and treatment of type 2 diabetes using lifestyle therapy, pharmacotherapy, and bariatric surgery: mechanisms of action. Curr Obes Rep. 2015;4(2):287–302. doi:10.​1007/​s13679-015-0155-x.PubMedCrossRef
130.
Stevens JW, Khunti K, Harvey R, Johnson M, Preston L, Woods HB, Davies M, Goyder E. Preventing the progression to type 2 diabetes mellitus in adults at high risk: a systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions. Diabetes Res Clin Pract. 2015;107(3):320–31. doi:10.​1016/​j.​diabres.​2015.​01.​027.PubMedCrossRef
Metadata
Title
Adipokine Pattern After Bariatric Surgery: Beyond the Weight Loss
Authors
Gian Franco Adami
Nicola Scopinaro
Renzo Cordera
Publication date
01-11-2016
Publisher
Springer US
Published in
Obesity Surgery / Issue 11/2016
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-016-2347-1

Other articles of this Issue 11/2016

Obesity Surgery 11/2016 Go to the issue

Original Contributions

Laparoscopic Sleeve Gastrectomy and Gastric Bypass for The Aging Population

Original Contributions

Influence of Roux-en-Y Gastric Bypass on the Hepatocellular Function and Bile Flow of Obese Patients Assessed by Scintigraphy with DISIDA

Original Contributions

Portomesenteric Vein Thrombosis After Laparoscopic Sleeve Gastrectomy: Incidence, Analysis and Follow-Up in 1236 Consecutive Cases

Original Contributions

Patient Perspectives About Follow-Up Care and Weight Regain Following Sleeve Gastrectomy

Letter to the Editor

The Clinical Dilemma of Calcium Supplementation After Bariatric Surgery: Calcium Citrate or Calcium Carbonate That Is the Question?

Original Contributions

Usefulness of Baltasar’s expected body mass index as an indicator of bariatric weight loss surgery